IDEXX LABORATORIES INC /DE
About IDEXX LABORATORIES INC /DE
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $4.3B
- Net income
- $1.1B
- Total assets
- $3.4B
- Market cap
- $44.3B
- Gross margin
- 61.8%
- Operating margin
- 31.6%
- Net margin
- 24.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.3B
- Cost of revenue
- $1.6B
- Gross profit
- $2.7B
- Operating expenses
- $1.3B
- Operating income
- $1.4B
- Income tax
- $264.7M
- Net income
- $1.1B
- EPS (basic)
- $13.17
- EPS (diluted)
- $13.08
Balance sheet
- Total assets
- $3.4B
- Current assets
- $1.4B
- Total liabilities
- $1.7B
- Current liabilities
- $1.1B
- Shareholders’ equity
- $1.6B
Cash flow
- Operating cash flow
- $1.2B
- Investing cash flow
- -$136.2M
- Financing cash flow
- -$1.2B
- Net cash flow
- -$108.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $44.3B
- P/E ratio
- 42.9
- EPS (diluted)
- $13.08
- Shares outstanding
- 79.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 21, 1991
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.1B in FY2025.
- Revenue grew 34% from FY2021 to FY2025.
- Gross margin of 61.8%, net margin 24.6%.
- Trading 27% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 42.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review IDEXX LABORATORIES INC /DE.
Write a review
News about IDEXX LABORATORIES INC /DE
News & sentiment via Polygon.io
